Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, our customers and our industry partners.

Noven has over 650 employees working in facilities located in: Miami, FL; New York, NY; and Carlsbad, CA, and in sales force territories located across the U.S. Noven is an indirect wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., and Noven serves as Hisamitsu's growth platform in U.S. prescription pharmaceuticals. Noven’s business and operations are focused in three principal areas – transdermal drug development and manufacturing, the Novogyne joint venture with Novartis Pharmaceuticals Corporation, and Noven Therapeutics, Noven’s specialty pharmaceutical unit.

Noven’s commercialized transdermal products include Vivelle-Dot^® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., Daytrana^® (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD, and our Fentanyl transdermal system. Noven’s commercialized oral products consist of Stavzor^® (delayed release valproic acid softgel), Pexeva^® (paroxetine mesylate) and Lithobid^® (lithium carbonate). Noven’s product development pipeline includes a range of prescription transdermal products, and the oral product Mesafem™, currently in Phase 3 development for the treatment of vasomotor symptoms (hot flashes) associated with menopause.

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.